Trial Profile
Safety and efficacy of anti-thymocyte globulin for graft-versus-host disease prophylaxis in mismatched and matched unrelated hematopoietic peripheral stem cell transplantation for hematologic malignancies: An observational study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Jun 2018
Price :
$35
*
At a glance
- Drugs Antithymocyte globulin (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 29 Jun 2018 New trial record